A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer;   Renal Cell Carcinoma
Interventions:   Drug: AB928;   Drug: AB122
Sponsor:   Arcus Biosciences, Inc.
Recruiting

https://ift.tt/2Ba8jVF